查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1600159

分子诊断市场：按技术、产品、应用和最终用户划分 - 全球预测 2025-2030

Molecular Diagnostics Market by Technology (Chips and Microarrays, In Situ Hybridization, Mass Spectrometry (MS)), Product (Instruments, Reagents), Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年分子诊断市值为315.9亿美元，预计2024年将达到363亿美元，复合年增长率为15.82%，预计到2030年将达到883.6亿美元。

分子诊断的范围包括使用分子生物学技术分析遗传物质和蛋白质来诊断和监测疾病、评估特定疾病的风险并确定预后的广泛测试。作为个人化医疗的重要工具，它的需求在于其准确性和提供早期准确诊断并实现客製化治疗策略的能力。分子诊断应用于感染疾病检测、肿瘤学、基因检测和药物基因组学，并交付给医院、实验室、研究机构和製药公司等最终用户。该市场受到感染疾病和癌症的增加、分子诊断技术的技术进步以及对个人化医疗日益增长的兴趣的影响。

主要市场统计
基准年[2023] 315.9亿美元
预测年份 [2024] 363亿美元
预测年份 [2030] 883.6亿美元
复合年增长率（%） 15.82%

最近出现的机会是将人工智慧和机器学习整合到诊断平台中，以增强资料分析和预测能力。为应对这场流行病而建立的检测开发策略联盟和增加政府资金也指出了成长的途径。然而，高测试成本、严格的监管核准以及对先进基础设施的需求等限制因素可能会限制采用，特别是在资源匮乏的环境中。开拓标准化通讯协定和改善新兴市场的准入是应对这些挑战的重要步骤。

具有创新潜力的领域包括就地检验、具有成本效益的定序技术以及导致新诊断测试的生物标记发现。生物技术公司和医疗保健提供者之间的伙伴关係可以加速这些创新的开发和实施。分子诊断市场本质上是动态的，受到快速技术发展和医疗保健领域转向以诊断为中心的方法的推动。公司可以透过专注于扩大其检测产品组合以纳入罕见疾病并利用数位健康技术来优化工作流程和改善患者治疗结果来建立战略地位。继续适应快速发展的科学进步和监管环境是维持该领域业务成长的关键。

市场动态：揭示快速发展的分子诊断市场的关键市场洞察

供需的动态交互作用正在改变分子诊断市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 感染疾病及各种癌症盛行率高 医院感染盛行率
    • 政府津贴增加
    • 照护现场的需求增加
  • 市场限制因素
    • 缺乏清晰统一的法律规范
    • 训练有素的专业人员效率低下限制了新分子诊断技术的适当使用
  • 市场机会
    • 分子诊断技术的进步和疾病早期诊断意识的提高
    • 活性化新兴国家的研发活动
  • 市场问题
    • 新分子诊断测试的核准延迟
    • 核准流程严格规定

波特五力：驾驭分子诊断市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解分子诊断市场的外部影响

外部宏观环境因素在塑造分子诊断市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解分子诊断市场的竞争格局

对分子诊断市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：分子诊断市场供应商绩效评估

FPNV定位矩阵是评估分子诊断市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製分子诊断市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，分子诊断市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 感染疾病和各种癌症盛行率高，医院感染盛行率高
      • 政府资助增加
      • 照护现场的需求增加
    • 抑制因素
      • 缺乏清晰统一的法规结构
      • 训练有素的专业人员效率低下限制了新分子诊断技术的适当使用
    • 机会
      • 分子诊断技术的进步和疾病早期诊断意识的提高
      • 新兴国家研发活动增加
    • 任务
      • 新分子诊断测试的核准延迟
      • 严格的核准流程规定
  • 市场区隔分析
    • 技术：扩大次世代定序在个人化医疗和标靶治疗的应用
    • 应用：将分子诊断整合到精准医学中，用于感染疾病的早期疗育
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章分子诊断市场：依技术分类

  • 介绍
  • 晶片和微阵列
  • 原位杂合反应
  • 质谱（MS）
  • PCR
  • 定序

第七章分子诊断市场：副产品

  • 介绍
  • 装置
  • 试剂

第八章分子诊断市场：依应用分类

  • 介绍
  • 验血
  • 遗传疾病筛检
  • 人类白血球抗原分型
  • 感染疾病
  • 微生物学
  • 肿瘤学
  • 药物基因组学

第九章分子诊断市场：依最终用户分类

  • 介绍
  • 医院
  • 研究所

第十章美洲分子诊断市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太分子诊断市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲分子诊断市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Guardant Health 推出 Guardant360 TissueNext 测试，包含近 500 个生物标记
    • QIAGEN 和 Myriad Genetics 合作开发全球使用的同源重组缺陷测试
    • Labcorp 推出针对早期大肠直肠癌的临床检验ctDNA 解决方案
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • ADT BIoTech
  • Agilent Technologies Inc.
  • Becton, Dickinson, and Company
  • Bio-Rad Laboratories, Inc.
  • Biocartis Group NV
  • bioMerieux SA
  • Danaher Corporation
  • DiaSorin SpA
  • Grifols SA
  • Hologic Inc.
  • Illumina, Inc.
  • Johnson & Johnson
  • LabCorp
  • Myriad Genetics, Inc.
  • Novartis AG
  • Roche Diagnostics Corporation
  • Siemens Healthineers
  • Sysmex Corporation by Oxford Gene Technology
  • Thermo Fisher Scientific Inc.
Product Code: MRR-434CCDA04D46

The Molecular Diagnostics Market was valued at USD 31.59 billion in 2023, expected to reach USD 36.30 billion in 2024, and is projected to grow at a CAGR of 15.82%, to USD 88.36 billion by 2030.

The scope of molecular diagnostics encompasses a wide range of tests that utilize molecular biology techniques to analyze genetic material and proteins to diagnose and monitor diseases, assess the risk of developing certain conditions, and determine prognosis. As a crucial tool in personalized medicine, its necessity lies in its precision and ability to provide early and accurate diagnosis, enabling tailored therapeutic strategies. Molecular diagnostics find applications in infectious disease detection, oncology, genetic testing, and pharmacogenomics, catering to end-users such as hospitals, laboratories, research institutions, and pharmaceutical companies. The market is influenced by increasing incidences of infectious diseases and cancer, technological advancements in molecular diagnostic techniques, and a growing focus on personalized medicine.

KEY MARKET STATISTICS
Base Year [2023] USD 31.59 billion
Estimated Year [2024] USD 36.30 billion
Forecast Year [2030] USD 88.36 billion
CAGR (%) 15.82%

Recent opportunities emerge from the integration of artificial intelligence and machine learning with diagnostic platforms, enhancing data analysis and predictive capabilities. Strategic collaborations for assay development and increased government funding in pandemic preparedness also present growth avenues. However, the market faces limitations due to high costs of tests, stringent regulatory approvals, and the need for sophisticated infrastructure, which can restrict adoption particularly in low-resource settings. Developing standardized protocols and improving access in emerging markets are crucial steps to addressing these challenges.

Innovation areas with potential include point-of-care testing solutions, cost-effective sequencing technologies, and biomarker discovery that can lead to novel diagnostic tests. Partnerships between biotech firms and healthcare providers can expedite the development and implementation of these innovations. The molecular diagnostics market is intrinsically dynamic, driven by rapid technological evolution and a shift towards a more diagnostic-centric approach in healthcare. Businesses can strategically position themselves by focusing on expanding their assay portfolios to include rare diseases and by leveraging digital health technologies to optimize workflows and improve patient outcomes. Remaining adaptable to burgeoning scientific advancements and regulatory landscapes will be key to sustaining business growth in this field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Molecular Diagnostics Market

The Molecular Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • High prevalence of infectious diseases and various types of cancers prevalence rate of hospital-acquired infections
    • Escalation in government funding
    • Increasing demand for point of care diagnostics
  • Market Restraints
    • Lack of clear and uniform regulatory framework
    • Inefficiency of trained professionals limiting the appropriate use of new molecular diagnostic technologies
  • Market Opportunities
    • Technological advancements in molecular diagnostics along with increasing awareness towards early disease diagnosis
    • Rising number of R&D activities in the emerging economies
  • Market Challenges
    • Delay in the approval of new molecular diagnostic tests
    • Stringent regulations associated with the approval process

Porter's Five Forces: A Strategic Tool for Navigating the Molecular Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Molecular Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Molecular Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Molecular Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Molecular Diagnostics Market

A detailed market share analysis in the Molecular Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Molecular Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Molecular Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Molecular Diagnostics Market

A strategic analysis of the Molecular Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Molecular Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ADT Biotech, Agilent Technologies Inc., Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc., Biocartis Group NV, bioMerieux SA, Danaher Corporation, DiaSorin S.p.A., Grifols S.A., Hologic Inc., Illumina, Inc., Johnson & Johnson, LabCorp, Myriad Genetics, Inc., Novartis AG, Roche Diagnostics Corporation, Siemens Healthineers, Sysmex Corporation by Oxford Gene Technology, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Molecular Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Chips and Microarrays, In Situ Hybridization, Mass Spectrometry (MS), PCR, and Sequencing.
  • Based on Product, market is studied across Instruments and Reagents.
  • Based on Application, market is studied across Blood Screening, Genetic Disease Screening, Human Leukocyte Antigen Typing, Infectious Disease, Microbiology, Oncology, and Pharmacogenomics.
  • Based on End User, market is studied across Hospitals and Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High prevalence of infectious diseases and various types of cancers prevalence rate of hospital-acquired infections
      • 5.1.1.2. Escalation in government funding
      • 5.1.1.3. Increasing demand for point of care diagnostics
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of clear and uniform regulatory framework
      • 5.1.2.2. Inefficiency of trained professionals limiting the appropriate use of new molecular diagnostic technologies
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in molecular diagnostics along with increasing awareness towards early disease diagnosis
      • 5.1.3.2. Rising number of R&D activities in the emerging economies
    • 5.1.4. Challenges
      • 5.1.4.1. Delay in the approval of new molecular diagnostic tests
      • 5.1.4.2. Stringent regulations associated with the approval process
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology: Expanding use of next-generation sequencing in personalized medicine and targeted therapies
    • 5.2.2. Applications: Integration of molecular diagnostics in precision medicine for early intervention of infectious diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Molecular Diagnostics Market, by Technology

  • 6.1. Introduction
  • 6.2. Chips and Microarrays
  • 6.3. In Situ Hybridization
  • 6.4. Mass Spectrometry (MS)
  • 6.5. PCR
  • 6.6. Sequencing

7. Molecular Diagnostics Market, by Product

  • 7.1. Introduction
  • 7.2. Instruments
  • 7.3. Reagents

8. Molecular Diagnostics Market, by Application

  • 8.1. Introduction
  • 8.2. Blood Screening
  • 8.3. Genetic Disease Screening
  • 8.4. Human Leukocyte Antigen Typing
  • 8.5. Infectious Disease
  • 8.6. Microbiology
  • 8.7. Oncology
  • 8.8. Pharmacogenomics

9. Molecular Diagnostics Market, by End User

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Laboratories

10. Americas Molecular Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Molecular Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Molecular Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Guardant Health launches Guardant360 TissueNext test with nearly 500 biomarkers
    • 13.3.2. QIAGEN and Myriad Genetics collaborate on Homologous Recombination Deficiency Test for Global Use
    • 13.3.3. Labcorp launches clinically validated ctDNA solution for early-stage colon cancer
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. ADT Biotech
  • 3. Agilent Technologies Inc.
  • 4. Becton, Dickinson, and Company
  • 5. Bio-Rad Laboratories, Inc.
  • 6. Biocartis Group NV
  • 7. bioMerieux SA
  • 8. Danaher Corporation
  • 9. DiaSorin S.p.A.
  • 10. Grifols S.A.
  • 11. Hologic Inc.
  • 12. Illumina, Inc.
  • 13. Johnson & Johnson
  • 14. LabCorp
  • 15. Myriad Genetics, Inc.
  • 16. Novartis AG
  • 17. Roche Diagnostics Corporation
  • 18. Siemens Healthineers
  • 19. Sysmex Corporation by Oxford Gene Technology
  • 20. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. MOLECULAR DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. MOLECULAR DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MOLECULAR DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MOLECULAR DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY CHIPS AND MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY (MS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY BLOOD SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC DISEASE SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HUMAN LEUKOCYTE ANTIGEN TYPING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 196. MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023